St. Petersburg Research Institute of Emergency Medicine   Report issue

Academic/Hospital Phase 3
Founded: St. Petersburg Russian Federation (1919)

Organization Overview

First Clinical Trial
2017
NCT03849664
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

St. Petersburg Research Institute of Emergency Medicine n.a. I.I. Dzhanelidze

Active Ingredients

Drugs in Phase 3 Trials (4)

inosine (1 trial)

nicotinamide (1 trial)

riboflavin (1 trial)

sodium succinate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 4